Clinical trial · no report yet · Phase 3
EVOKE-SCLC-04
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT06801834 ↗
- Recruiting
- Gilead Sciences
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG); Topotecan; Amrubicin (Japan only); Lurbinectedin (regions/countries where approved and available)
- Arms
- Treatment Group A: SG · Experimental
- Treatment Group B: Topotecan, or Lurbinectedin, or Amrubicin · Experimental
- Enrollment
- 695 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Gilead Sciences
- Start
- Apr 4, 2025
- Primary completion
- Oct 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06801834 · updated Oct 20, 2026